Income statement
USD
Annual
| Metric | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | -157K | -120K | -67K | -32K |
| Operating Income | -76M | -49M | -21M | -11M |
| EBITDA | -76M | -48M | -21M | -11M |
| Net Income | -73M | -51M | -22M | -11M |
| EPS (Diluted) | — | — | — | — |
Healthcare
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 20, 2025 → Jun 16, 2026
Coverage: 248 bars · Jun 20, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sienna Biopharmaceuticals, Inc. (SNNAQ) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 20, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +30.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +30.8%, free cash flow -49.3% with operating margin 0.0% and ROIC -92.0%. Stock Foundry combines SNNAQ price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SNNAQ
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SNNAQ Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SNNAQ and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$11.3M
+48.3% YoY
Free Cash Flow
-$10.1M
+43.8% YoY
Revenue Growth
+0.0%
EPS Growth
+30.8%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | -157K | -120K | -67K | -32K |
| Operating Income | -76M | -49M | -21M | -11M |
| EBITDA | -76M | -48M | -21M | -11M |
| Net Income | -73M | -51M | -22M | -11M |
| EPS (Diluted) | — | — | — | — |
Balance sheet
USD
| Metric | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|
| Cash & Equivalents | 49M | 74M | 9M | 5M |
| Total Assets | 107M | 137M | 62M | 6M |
| Total Liabilities | 81M | 46M | 40M | 2M |
| Shareholder Equity | 159M | 86M | 22M | 4M |
| Total Debt | 30M | 0 | 0 | 0 |
| Net Debt | -18M | -74M | -9M | -5M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
10M
+43.6% YoY
Capital Expenditures
88K
+63.0% YoY
Free Cash Flow
10M
+43.8% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-59.8%
Debt / Equity
0.19x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.